Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
| 대상 질환 | Asthma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | ARS Pharmaceuticals, Inc. |
| 상태 | 완료 |
| 참여자 수 | 18 명 |
| 중재(약물) | ARS-1 1 mg, Albuterol MDI, ARS-1 2mg |
| 시작일 | 2022년 7월 28일 |
| 완료일 | 2024년 2월 2일 |
| 결과 공개일 | 2026년 7월 14일 |
요약
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Effect of ARS-1 Versus Albuterol and Placebo
| ARS-1 1mg | 0.150 ± 0.223 FEV1 L per hour |
|---|---|
| ARS-1 2mg | 0.233 ± 0.216 FEV1 L per hour |
| Placebo | -0.002 ± 0.118 FEV1 L per hour |
| Albuterol | 0.378 ± 0.265 FEV1 L per hour |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca